– USA, CA – Cytokinetics, Incorporated (NASDAQ: CYTK) today announced the appointment of Muna Bhanji to its Board of Directors, bringing more than 30 years of strategic and operational experience in the biopharmaceutical industry with a proven track record of commercial leadership, growth and value creation.
“We are pleased to welcome Muna to our Board,” said CEO, Robert Blum. “As a veteran commercial leader with demonstrated expertise in institutional and specialty market sectors as well as innovative commercial models shaped by a focus on value demonstration and patient access, her guidance relative to our continued corporate and commercial development should prove especially valuable. In particular, we look forward to her insights to inform how our company may best ensure optimal access and affordability to our potential medicines developed for patients with devastating diseases of impaired muscle function.”
About Muna Bhanji
Ms. Bhanji built her career at Merck with leadership experiences spanning US-based sales, marketing, and commercial operations, as well as global franchise business units and global market access and policy, across a diverse portfolio of medicines and vaccines.
Most recently, Muna Bhanji served as SVP, Global Market Access and Policy, at Merck, leading the organization to enable access and payer reimbursement for the medicines and vaccines. During her tenure at the company, Ms. Bhanji has held senior leadership roles of increasing responsibility overseeing the US and global business units, including sales, marketing, managed care, and commercial operations as well as serving as the Head of Merck’s Oncology and Hospital and Specialty businesses. Ms. Bhanji is recognized for building and overseeing industry-leading corporate capabilities and developing partnerships with key stakeholders to ensure equitable access to novel medicines and vaccines.
In addition to her extensive commercial leadership roles, she has served on the Board of the Foundation of Managed Care Pharmacy and has chaired Merck’s Supervisory Board in the Netherlands. Muna currently serves on the Board of Corus International, an ensemble of faith-based organizations working in concert to deliver the holistic, lasting solutions needed to overcome the interrelated challenges related to poverty and health.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies. Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following the conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is preparing for the potential advancement of reldesemtiv to a Phase 3 clinical trial. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused on diseases of muscle dysfunction and conditions of muscle weakness.
For more information : https://www.cytokinetics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
